[go: up one dir, main page]

WO2008105526A1 - マクロ環状化合物 - Google Patents

マクロ環状化合物 Download PDF

Info

Publication number
WO2008105526A1
WO2008105526A1 PCT/JP2008/053599 JP2008053599W WO2008105526A1 WO 2008105526 A1 WO2008105526 A1 WO 2008105526A1 JP 2008053599 W JP2008053599 W JP 2008053599W WO 2008105526 A1 WO2008105526 A1 WO 2008105526A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
disclosed
macrocyclic compound
useful
inhibitory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053599
Other languages
English (en)
French (fr)
Inventor
Nobuo Shimma
Takuo Tsukuda
Hiroshi Koyano
Atsushi Suda
Tadakatsu Hayase
Kihito Hada
Ken-Ichi Kawasaki
Susumu Komiyama
Naomi Ono
Toshikazu Yamazaki
Ryoichi Saitoh
Masami Kohchi
Kiyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08721047A priority Critical patent/EP2119718B1/en
Priority to US12/529,222 priority patent/US8362236B2/en
Priority to CN200880014171A priority patent/CN101675059A/zh
Priority to AT08721047T priority patent/ATE553107T1/de
Priority to BRPI0808524-2A2A priority patent/BRPI0808524A2/pt
Priority to JP2009501315A priority patent/JP5235859B2/ja
Priority to AU2008220009A priority patent/AU2008220009A1/en
Priority to CA002679126A priority patent/CA2679126A1/en
Priority to MX2009008756A priority patent/MX2009008756A/es
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of WO2008105526A1 publication Critical patent/WO2008105526A1/ja
Priority to IL200009A priority patent/IL200009A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

〔課題〕ＨＳＰ９０阻害作用を有し抗癌剤等として有用な新しいクラスの化合物、並びにその合成中間体として有用な化合物を提供すること。 〔解決手段〕本発明は、下記一般式（１）： 〔式中、Ｘ、Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、Ｒ６、Ｒ７、Ｌ１、Ｌ２、Ｌ３は、明細書に定義のとおりである。〕で表される化合物又はその薬学的に許容される塩を提供する。
PCT/JP2008/053599 2007-03-01 2008-02-29 マクロ環状化合物 Ceased WO2008105526A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002679126A CA2679126A1 (en) 2007-03-01 2008-02-29 Macrocyclic compound
US12/529,222 US8362236B2 (en) 2007-03-01 2008-02-29 Macrocyclic compound
CN200880014171A CN101675059A (zh) 2007-03-01 2008-02-29 大环状化合物
AT08721047T ATE553107T1 (de) 2007-03-01 2008-02-29 Makrocyclische verbindung
BRPI0808524-2A2A BRPI0808524A2 (pt) 2007-03-01 2008-02-29 Composto macrocíclico
EP08721047A EP2119718B1 (en) 2007-03-01 2008-02-29 Macrocyclic compound
AU2008220009A AU2008220009A1 (en) 2007-03-01 2008-02-29 Macrocyclic compound
JP2009501315A JP5235859B2 (ja) 2007-03-01 2008-02-29 マクロ環状化合物
MX2009008756A MX2009008756A (es) 2007-03-01 2008-02-29 Compuesto macrociclico.
IL200009A IL200009A0 (en) 2007-03-01 2009-07-22 Macrocyclic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-052072 2007-03-01
JP2007052072 2007-03-01

Publications (1)

Publication Number Publication Date
WO2008105526A1 true WO2008105526A1 (ja) 2008-09-04

Family

ID=39721348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053599 Ceased WO2008105526A1 (ja) 2007-03-01 2008-02-29 マクロ環状化合物

Country Status (18)

Country Link
US (1) US8362236B2 (ja)
EP (1) EP2119718B1 (ja)
JP (1) JP5235859B2 (ja)
KR (1) KR20090125155A (ja)
CN (1) CN101675059A (ja)
AR (1) AR065583A1 (ja)
AT (1) ATE553107T1 (ja)
AU (1) AU2008220009A1 (ja)
BR (1) BRPI0808524A2 (ja)
CA (1) CA2679126A1 (ja)
CL (1) CL2008000629A1 (ja)
IL (1) IL200009A0 (ja)
MX (1) MX2009008756A (ja)
PE (1) PE20090110A1 (ja)
RU (1) RU2009136343A (ja)
TW (1) TW200904435A (ja)
WO (1) WO2008105526A1 (ja)
ZA (1) ZA200905116B (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8193351B2 (en) 2006-05-26 2012-06-05 Chugai Seiyaku Kabushiki Kaisha HSP90 inhibitor
US8362236B2 (en) 2007-03-01 2013-01-29 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
US8680111B2 (en) 2012-03-06 2014-03-25 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
JP2015509970A (ja) * 2012-03-17 2015-04-02 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーション制約された全合成されたマクロ環化合物
WO2015046498A1 (ja) * 2013-09-30 2015-04-02 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん併用療法
WO2018207904A1 (ja) 2017-05-12 2018-11-15 中外製薬株式会社 環状有機化合物の製造方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617282B2 (en) 2013-03-15 2017-04-11 Biogen Ma Inc. Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005225787A (ja) * 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
JP2005530689A (ja) * 2002-02-08 2005-10-13 コンフォーマ・セラピューティクス・コーポレイション 改良された薬理学的および生物学的特性を有するアンサマイシン
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
WO2007138994A1 (ja) * 2006-05-26 2007-12-06 Chugai Seiyaku Kabushiki Kaisha Ｈｓｐ９０阻害剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
JPS60208968A (ja) 1984-03-07 1985-10-21 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 除草剤性フルオロエトキシピリミジン類及びトリアジン類
AU585761B2 (en) 1984-03-07 1989-06-22 E.I. Du Pont De Nemours And Company Herbicidal fluoroethoxy triazines
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
IL128516A0 (en) 1996-11-01 2000-01-31 Warner Lambert Co Isoquinolones
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
IL150912A0 (en) 2000-02-25 2003-02-12 Hoffmann La Roche Adenosine receptor modulators
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
WO2002036171A1 (en) 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
AU2877102A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Small molecule compositions for binding to hsp90
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
ES2559779T3 (es) 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
JP2008540626A (ja) 2005-05-19 2008-11-20 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2119718B1 (en) 2007-03-01 2012-04-11 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
NZ587207A (en) 2008-02-01 2012-05-25 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530689A (ja) * 2002-02-08 2005-10-13 コンフォーマ・セラピューティクス・コーポレイション 改良された薬理学的および生物学的特性を有するアンサマイシン
JP2005225787A (ja) * 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
WO2007138994A1 (ja) * 2006-05-26 2007-12-06 Chugai Seiyaku Kabushiki Kaisha Ｈｓｐ９０阻害剤

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193351B2 (en) 2006-05-26 2012-06-05 Chugai Seiyaku Kabushiki Kaisha HSP90 inhibitor
US8362236B2 (en) 2007-03-01 2013-01-29 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US9133215B2 (en) 2012-03-06 2015-09-15 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
US8680111B2 (en) 2012-03-06 2014-03-25 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
JP2015509970A (ja) * 2012-03-17 2015-04-02 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーション制約された全合成されたマクロ環化合物
US9694001B2 (en) 2013-09-30 2017-07-04 Taiho Pharmaceutical Co., Ltd. Combination therapy using azabicyclo compound for cancer
WO2015046498A1 (ja) * 2013-09-30 2015-04-02 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん併用療法
US10849886B2 (en) 2013-09-30 2020-12-01 Taiho Pharmaceutical Co., Ltd. Combination therapy using azabicyclo compound for cancer
US11166943B2 (en) 2013-09-30 2021-11-09 Taiho Pharmaceutical Co., Ltd. Combination therapy using azabicyclo compound for cancer
US11918562B2 (en) 2013-09-30 2024-03-05 Taiho Pharmaceutical Co., Ltd. Combination therapy using azabicyclo compound for cancer
WO2018207904A1 (ja) 2017-05-12 2018-11-15 中外製薬株式会社 環状有機化合物の製造方法
KR20200007863A (ko) 2017-05-12 2020-01-22 추가이 세이야쿠 가부시키가이샤 환상 유기 화합물의 제조 방법
CN110799523A (zh) * 2017-05-12 2020-02-14 中外制药株式会社 用于制备环状有机化合物的方法
JPWO2018207904A1 (ja) * 2017-05-12 2020-03-12 中外製薬株式会社 環状有機化合物の製造方法
JP2023052015A (ja) * 2017-05-12 2023-04-11 中外製薬株式会社 環状有機化合物の製造方法
US11807664B2 (en) 2017-05-12 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Also Published As

Publication number Publication date
CA2679126A1 (en) 2008-09-04
EP2119718A4 (en) 2010-12-15
AU2008220009A1 (en) 2008-09-04
US8362236B2 (en) 2013-01-29
ZA200905116B (en) 2010-07-28
US20100056510A1 (en) 2010-03-04
CL2008000629A1 (es) 2008-08-29
TW200904435A (en) 2009-02-01
JP5235859B2 (ja) 2013-07-10
CN101675059A (zh) 2010-03-17
EP2119718B1 (en) 2012-04-11
BRPI0808524A2 (pt) 2014-11-11
PE20090110A1 (es) 2009-04-04
RU2009136343A (ru) 2011-04-10
AR065583A1 (es) 2009-06-17
EP2119718A1 (en) 2009-11-18
KR20090125155A (ko) 2009-12-03
MX2009008756A (es) 2009-08-27
IL200009A0 (en) 2010-04-15
ATE553107T1 (de) 2012-04-15
JPWO2008105526A1 (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2008105526A1 (ja) マクロ環状化合物
WO2009020140A1 (ja) アダマンチルウレア誘導体
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2008120759A1 (ja) ウレア化合物およびその用途
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2006039164A3 (en) Novel cyclosporin analogues and their pharmaceutical uses
WO2008108386A1 (ja) 医薬組成物
WO2007135527A3 (en) Benzimidazolyl compounds
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2008079836A3 (en) Macrocyclic factor viia inhibitors useful as anticoagulants
TW200728307A (en) Novel spirochromanone derivatives
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2009063990A1 (ja) ベンズアゼピノン化合物
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2009020137A1 (ja) アミノピラゾールアミド誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880014171.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721047

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009501315

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200009

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12009501465

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 5004/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008756

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008220009

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2679126

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008721047

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008220009

Country of ref document: AU

Date of ref document: 20080229

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097020448

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009136343

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12529222

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0808524

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090831